ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+21.43%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$277M
AUM Growth
+$277M
(-24%)
Cap. Flow
-$56.8M
Cap. Flow
% of AUM
-20.47%
Top 10 Holdings %
Top 10 Hldgs %
45.56%
Holding
64
New
13
Increased
10
Reduced
20
Closed
17
Top Buys
| 1 |
VistaGen Therapeutics
VTGN
|
$10.2M |
| 2 |
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
|
$8.58M |
| 3 |
ESSA Pharma
EPIX
|
$8.34M |
| 4 |
Aclaris Therapeutics
ACRS
|
$8.01M |
| 5 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
$7.6M |
Top Sells
| 1 |
Larimar Therapeutics
LRMR
|
$18.5M |
| 2 |
Immunovant
IMVT
|
$13.1M |
| 3 |
Celldex Therapeutics
CLDX
|
$12.6M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
$10.3M |
| 5 |
SURF
Surface Oncology, Inc. Common Stock
SURF
|
$9.24M |
Sector Composition
| 1 | Healthcare | 91.38% |
| 2 | Financials | 5.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
VistaGen Therapeutics
VTGN
$102M
| $26.2M | 9.44% | 12,295,767 +4,795,767 | +64% | +$10.2M |
|
|
2
Celldex Therapeutics
CLDX
$1.47B
| $21M | 7.56% | 1,017,524 -609,976 | -37% | -$12.6M |
|
3
Kura Oncology
KURA
$686M
| $15.2M | 5.47% | 536,820 -100,680 | -16% | -$2.85M |
|
|
AVDL
4
Avadel Pharmaceuticals
AVDL
$1.43B
| $9.9M | 3.57% | 1,095,000 +389,782 | +55% | +$3.52M |
|
|
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.76M | 3.52% | 1,579,093 +366,593 | +30% | +$2.27M |
|
6
89bio
ETNB
$1.34B
| $9.32M | 3.36% | 393,548 -40,852 | -9% | -$967K |
|
|
BLSA
7
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $8.91M | 3.21% | 843,122 +622 | +0.1% | +$6.58K |
|
|
SAGE
8
DELISTED
Sage Therapeutics
SAGE
| $8.87M | 3.2% | 118,500 -137,300 | -54% | -$10.3M |
|
9
Curis
CRIS
$20.9M
| $8.69M | 3.13% | 767,500 +237,500 | +45% | +$2.69M |
|
|
SEEL
10
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $8.58M | 3.09% | +1,719,812 | New | +$8.58M |
|
|
11
ESSA Pharma
EPIX
$11.4M
| $8.34M | 3.01% | +287,000 | New | +$8.34M |
|
|
12
Aclaris Therapeutics
ACRS
$209M
| $8.01M | 2.89% | +317,730 | New | +$8.01M |
|
|
VINC
13
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $7.6M | 2.74% | +394,000 | New | +$7.6M |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $7.38M | 2.66% | 412,500 +332,500 | +416% | +$5.95M |
|
15
Athira Pharma
ATHA
$15.3M
| $7.36M | 2.65% | 400,000 +7,000 | +2% | +$129K |
|
16
Fulcrum Therapeutics
FULC
$351M
| $7.33M | 2.64% | 622,500 -60,000 | -9% | -$707K |
|
17
Arrowhead Research
ARWR
$3.05B
| $7.16M | 2.58% | 108,000 -31,000 | -22% | -$2.06M |
|
|
TRIL
18
DELISTED
Trillium Therapeutics Inc.
TRIL
| $7.11M | 2.56% | 661,565 -141,435 | -18% | -$1.52M |
|
|
CMRX
19
DELISTED
Chimerix, Inc.
CMRX
| $6.82M | 2.46% | +707,830 | New | +$6.82M |
|
20
Mersana Therapeutics
MRSN
$36.5M
| $5.79M | 2.09% | 357,689 -336,311 | -48% | -$5.44M |
|
21
Altimmune
ALT
$338M
| $5.75M | 2.07% | 407,055 -171,445 | -30% | -$2.42M |
|
22
Syndax Pharmaceuticals
SNDX
$1.41B
| $5.71M | 2.06% | 255,180 -210,320 | -45% | -$4.7M |
|
23
Verastem
VSTM
$569M
| $5.67M | 2.04% | 2,293,388 -106,612 | -4% | -$263K |
|
|
JYAC
24
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $5.54M | 2% | 562,500 | – | – |
|
25
Praxis Precision Medicines
PRAX
$958M
| $5.05M | 1.82% | 154,229 +78,584 | +104% | +$2.57M |
|